Shots:
- Health Canada has approved Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) ± docetaxel to treat mHSPC pts
- Approval was based on the P-III (ARANOTE) trial evaluating Nubeqa (600mg, BID) + ADT vs PBO + ADT in 669 mHSPC pts
- Trial showed a 46% reduction in rPFS (1EP), with consistent benefit observed across all subgroups, incl. pts with high-volume & low-volume disease; data was presented at ESMO’24 & published in The JCO
Ref: Bayer | Image: Bayer | Press Release
Related News:- Bayer Enters a ~$1.3B Deal with Kumquat Biosciences to Develop and Commercialize a KRAS G12D Inhibitor
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
